In addition to functional inhibitors, alternative strategies to counteract MCL-1 resistance have been explored, such as downregulation of MCL-1 expression by caloric restriction in B-cell lymphoma [105] or by cardiac glycoside UNBS1450 in AML [106]. This evidence concerns the gene MCL1 and acute myeloid leukemia.